Characterization	Characterization	NN	B-NP	O		0	16
of	of	IN	B-PP	O		17	19
a	a	DT	B-NP	O		20	21
lipopolysaccharide	lipopolysaccharide	NN	I-NP	B-protein		22	40
-	-	HYPH	O	I-protein		40	41
targeted	target	VBN	B-VP	I-protein		41	49
monoclonal	monoclonal	JJ	B-NP	I-protein		50	60
antibody	antibody	NN	I-NP	I-protein		61	69
and	and	CC	O	O		70	73
its	its	PRP$	B-NP	O		74	77
variable	variable	JJ	I-NP	O		78	86
fragments	fragment	NNS	I-NP	O		87	96
as	as	IN	B-PP	O		97	99
candidates	candidate	NNS	B-NP	O		100	110
for	for	IN	B-PP	O		111	114
prophylaxis	prophylaxis	NN	B-NP	O		115	126
against	against	IN	B-PP	O		127	134
the	the	DT	B-NP	O		135	138
obligate	obligate	JJ	I-NP	O		139	147
intracellular	intracellular	JJ	I-NP	O		148	161
bacterial	bacterial	JJ	I-NP	O		162	171
pathogen	pathogen	NN	I-NP	O		172	180
Coxiella burnetii	Coxiella_burnetii	NNP	I-NP	O		181	198
.	.	.	O	O		198	199

Our	Our	PRP$	B-NP	O		200	203
previous	previous	JJ	I-NP	O		204	212
study	study	NN	I-NP	O		213	218
demonstrated	demonstrate	VBD	B-VP	O		219	231
that	that	IN	B-SBAR	O		232	236
treatment	treatment	NN	B-NP	O		237	246
of	of	IN	B-PP	O		247	249
Coxiella burnetii	Coxiella_burnetii	NNP	B-NP	O		250	267
with	with	IN	B-PP	O		268	272
the	the	DT	B-NP	O		273	276
phase	phase	NN	I-NP	O		277	282
I	I	CD	I-NP	O		283	284
lipopolysaccharide	lipopolysaccharide	NN	I-NP	O		285	303
(	(	(	O	O		304	305
PI	PI	NN	B-NP	O		305	307
-	-	HYPH	O	O		307	308
LPS	LPS	NN	B-NP	O		308	311
)	)	)	O	O		311	312
-	-	HYPH	O	O		312	313
targeted	target	VBN	B-VP	O		313	321
monoclonal	monoclonal	JJ	B-NP	B-protein		322	332
antibody	antibody	NN	I-NP	I-protein		333	341
(	(	(	O	O		342	343
MAb	MAb	NN	B-NP	B-protein		343	346
)	)	)	O	O		346	347
1E4	1E4	NN	B-NP	O		348	351
significantly	significantly	RB	B-ADVP	O		352	365
inhibited	inhibit	VBD	B-VP	O		366	375
C. burnetii	C._burnetii	NN	B-NP	O		376	387
infection	infection	NN	I-NP	O		388	397
in	in	IN	B-PP	O		398	400
mice	mouse	NNS	B-NP	O		401	405
,	,	,	O	O		405	406
suggesting	suggest	VBG	B-VP	O		407	417
that	that	IN	B-SBAR	O		418	422
1E4	1E4	NN	B-NP	B-protein		423	426
is	be	VBZ	B-VP	O		427	429
a	a	DT	B-NP	O		430	431
protective	protective	JJ	I-NP	B-protein		432	442
MAb	MAb	NN	I-NP	I-protein		443	446
.	.	.	O	O		446	447

To	To	TO	B-VP	O		448	450
determine	determine	VB	I-VP	O		451	460
whether	whether	IN	B-SBAR	O		461	468
passive	passive	JJ	B-NP	O		469	476
transfer	transfer	NN	I-NP	O		477	485
of	of	IN	B-PP	O		486	488
antibodies	antibody	NNS	B-NP	B-protein		489	499
(	(	(	O	O		500	501
Abs	Ab	NNS	B-NP	B-protein		501	504
)	)	)	O	O		504	505
can	can	MD	B-VP	O		506	509
provide	provide	VB	I-VP	O		510	517
protection	protection	NN	B-NP	O		518	528
against	against	IN	B-PP	O		529	536
C. burnetii	C._burnetii	NNP	B-NP	O		537	548
natural	natural	JJ	I-NP	O		549	556
infection	infection	NN	I-NP	O		557	566
,	,	,	O	O		566	567
we	we	PRP	B-NP	O		568	570
examined	examine	VBD	B-VP	O		571	579
if	if	IN	B-SBAR	O		580	582
passive	passive	JJ	B-NP	O		583	590
transfer	transfer	NN	I-NP	O		591	599
of	of	IN	B-PP	O		600	602
1E4	1E4	NN	B-NP	B-protein		603	606
would	would	MD	B-VP	O		607	612
protect	protect	VB	I-VP	O		613	620
SCID	SCID	NN	B-NP	O		621	625
mice	mouse	NNS	I-NP	O		626	630
against	against	IN	B-PP	O		631	638
C. burnetii	C._burnetii	NNP	B-NP	O		639	650
aerosol	aerosol	NN	I-NP	O		651	658
infection	infection	NN	I-NP	O		659	668
.	.	.	O	O		668	669

The	The	DT	B-NP	O		670	673
results	result	NNS	I-NP	O		674	681
indicated	indicate	VBD	B-VP	O		682	691
that	that	IN	B-SBAR	O		692	696
1E4	1E4	NN	B-NP	B-protein		697	700
conferred	confer	VBD	B-VP	O		701	710
significant	significant	JJ	B-NP	O		711	722
protection	protection	NN	I-NP	O		723	733
against	against	IN	B-PP	O		734	741
aerosolized	aerosolize	VBN	B-NP	O		742	753
C. burnetii	C._burnetii	NNP	I-NP	O		754	765
,	,	,	O	O		765	766
suggesting	suggest	VBG	B-VP	O		767	777
that	that	IN	B-SBAR	O		778	782
1E4	1E4	NN	B-NP	B-protein		783	786
may	may	MD	B-VP	O		787	790
be	be	VB	I-VP	O		791	793
useful	useful	JJ	B-ADJP	O		794	800
for	for	IN	B-PP	O		801	804
preventing	prevent	VBG	B-VP	O		805	815
C. burnetii	C._burnetii	NNP	B-NP	O		816	827
natural	natural	JJ	I-NP	O		828	835
infection	infection	NN	I-NP	O		836	845
.	.	.	O	O		845	846

To	To	TO	B-VP	O		847	849
further	further	RB	I-VP	O		850	857
understand	understand	VB	I-VP	O		858	868
the	the	DT	B-NP	O		869	872
mechanisms	mechanism	NNS	I-NP	O		873	883
of	of	IN	B-PP	O		884	886
1E4	1E4	NN	B-NP	B-protein		887	890
-	-	HYPH	O	O		890	891
mediated	mediate	VBN	B-NP	O		891	899
protection	protection	NN	I-NP	O		900	910
and	and	CC	O	O		911	914
to	to	TO	B-VP	O		915	917
test	test	VB	I-VP	O		918	922
the	the	DT	B-NP	O		923	926
possibility	possibility	NN	I-NP	O		927	938
of	of	IN	B-PP	O		939	941
using	use	VBG	B-VP	O		942	947
humanized	humanized	JJ	B-NP	B-protein		948	957
1E4	1E4	NN	I-NP	I-protein		958	961
to	to	TO	B-VP	O		962	964
prevent	prevent	VB	I-VP	O		965	972
C. burnetii	C._burnetii	NNP	B-NP	O		973	984
infection	infection	NN	I-NP	O		985	994
,	,	,	O	O		994	995
we	we	PRP	B-NP	O		996	998
examined	examine	VBD	B-VP	O		999	1007
whether	whether	IN	B-SBAR	O		1008	1015
the	the	DT	B-NP	O		1016	1019
Fab	Fab	NNP	I-NP	O		1020	1023
fragment	fragment	NN	I-NP	O		1024	1032
of	of	IN	B-PP	O		1033	1035
1E4	1E4	NN	B-NP	B-protein		1036	1039
(	(	(	O	O		1040	1041
Fab1E4	Fab1E4	NN	B-NP	B-protein		1041	1047
)	)	)	O	O		1047	1048
,	,	,	O	O		1048	1049
a	a	DT	B-NP	O		1050	1051
recombinant	recombinant	JJ	I-NP	B-DNA		1052	1063
murine	murine	JJ	I-NP	I-DNA		1064	1070
single	single	JJ	I-NP	I-DNA		1071	1077
-	-	HYPH	I-NP	I-DNA		1077	1078
chain	chain	NN	I-NP	I-DNA		1078	1083
variable	variable	JJ	I-NP	I-DNA		1084	1092
fragment	fragment	NN	I-NP	I-DNA		1093	1101
(	(	(	O	O		1102	1103
muscFv1E4	muscFv1E4	NN	B-NP	B-protein		1103	1112
)	)	)	O	O		1112	1113
,	,	,	O	O		1113	1114
and	and	CC	O	O		1115	1118
a	a	DT	B-NP	O		1119	1120
humanized	humanized	JJ	I-NP	B-DNA		1121	1130
single	single	JJ	I-NP	I-DNA		1131	1137
-	-	HYPH	I-NP	I-DNA		1137	1138
chain	chain	NN	I-NP	I-DNA		1138	1143
variable	variable	JJ	I-NP	I-DNA		1144	1152
fragment	fragment	NN	I-NP	I-DNA		1153	1161
(	(	(	O	O		1162	1163
huscFv1E4	huscFv1E4	NN	B-NP	O		1163	1172
)	)	)	O	O		1172	1173
retained	retain	VBD	B-VP	O		1174	1182
the	the	DT	B-NP	O		1183	1186
ability	ability	NN	I-NP	O		1187	1194
of	of	IN	B-PP	O		1195	1197
1E4	1E4	NN	B-NP	B-protein		1198	1201
to	to	TO	B-VP	O		1202	1204
inhibit	inhibit	VB	I-VP	O		1205	1212
C. burnetii	C._burnetii	NN	B-NP	O		1213	1224
infection	infection	NN	I-NP	O		1225	1234
.	.	.	O	O		1234	1235

The	The	DT	B-NP	O		1236	1239
results	result	NNS	I-NP	O		1240	1247
indicated	indicate	VBD	B-VP	O		1248	1257
that	that	IN	B-SBAR	O		1258	1262
Fab1E4	Fab1E4	NN	B-NP	B-protein		1263	1269
,	,	,	O	O		1269	1270
muscFv1E4	muscFv1E4	NN	B-NP	O		1271	1280
,	,	,	O	O		1280	1281
and	and	CC	O	O		1282	1285
huscFv1E4	huscFv1E4	NN	B-NP	B-protein		1286	1295
were	be	VBD	B-VP	O		1296	1300
able	able	JJ	B-ADJP	O		1301	1305
to	to	TO	B-VP	O		1306	1308
inhibit	inhibit	VB	I-VP	O		1309	1316
C. burnetii	C._burnetii	NN	B-NP	O		1317	1328
infection	infection	NN	I-NP	O		1329	1338
in	in	IN	B-PP	O		1339	1341
mice	mouse	NNS	B-NP	O		1342	1346
but	but	CC	O	O		1347	1350
that	that	DT	O	O		1351	1355
their	their	PRP$	B-NP	O		1356	1361
ability	ability	NN	I-NP	O		1362	1369
to	to	TO	B-VP	O		1370	1372
inhibit	inhibit	VB	I-VP	O		1373	1380
C. burnetii	C._burnetii	NN	B-NP	O		1381	1392
infection	infection	NN	I-NP	O		1393	1402
was	be	VBD	B-VP	O		1403	1406
lower	low	JJR	B-ADJP	O		1407	1412
than	than	IN	B-PP	O		1413	1417
that	that	DT	B-NP	O		1418	1422
of	of	IN	B-PP	O		1423	1425
1E4	1E4	NN	B-NP	B-protein		1426	1429
.	.	.	O	O		1429	1430

In	In	IN	B-PP	O		1431	1433
addition	addition	NN	B-NP	O		1434	1442
,	,	,	O	O		1442	1443
treatment	treatment	NN	B-NP	O		1444	1453
of	of	IN	B-PP	O		1454	1456
C. burnetii	C._burnetii	NN	B-NP	O		1457	1468
with	with	IN	B-PP	O		1469	1473
Fab1E4	Fab1E4	NN	B-NP	O		1474	1480
,	,	,	O	O		1480	1481
muscFv1E4	muscFv1E4	NN	B-NP	O		1482	1491
,	,	,	O	O		1491	1492
or	or	CC	O	O		1493	1495
huscFv1E4	huscFv1E4	NN	B-NP	O		1496	1505
can	can	MD	B-VP	O		1506	1509
block	block	VB	I-VP	O		1510	1515
C. burnetii	C._burnetii	NNP	B-NP	O		1516	1527
infection	infection	NN	I-NP	O		1528	1537
of	of	IN	B-PP	O		1538	1540
macrophages	macrophage	NNS	B-NP	B-cell_type		1541	1552
.	.	.	O	O		1552	1553

Interestingly	Interestingly	RB	B-ADVP	O		1554	1567
,	,	,	O	O		1567	1568
treatment	treatment	NN	B-NP	O		1569	1578
of	of	IN	B-PP	O		1579	1581
C. burnetii	C._burnetii	NN	B-NP	O		1582	1593
with	with	IN	B-PP	O		1594	1598
huscFv1E4	huscFv1E4	NN	B-NP	B-protein		1599	1608
can	can	MD	B-VP	O		1609	1612
significantly	significantly	RB	I-VP	O		1613	1626
reduce	reduce	VB	I-VP	O		1627	1633
C. burnetii	C._burnetii	NN	B-NP	O		1634	1645
infectivity	infectivity	NN	I-NP	O		1646	1657
in	in	IN	B-PP	O		1658	1660
human	human	JJ	B-NP	B-cell_type		1661	1666
macrophages	macrophage	NNS	I-NP	I-cell_type		1667	1678
.	.	.	O	O		1678	1679

This	This	DT	B-NP	O		1680	1684
report	report	NN	I-NP	O		1685	1691
provides	provide	VBZ	B-VP	O		1692	1700
the	the	DT	B-NP	O		1701	1704
first	first	JJ	I-NP	O		1705	1710
evidence	evidence	NN	I-NP	O		1711	1719
to	to	TO	B-VP	O		1720	1722
demonstrate	demonstrate	VB	I-VP	O		1723	1734
that	that	IN	B-SBAR	O		1735	1739
the	the	DT	B-NP	O		1740	1743
humanized	humanized	JJ	I-NP	B-DNA		1744	1753
variable	variable	JJ	I-NP	I-DNA		1754	1762
fragments	fragment	NNS	I-NP	I-DNA		1763	1772
of	of	IN	B-PP	O		1773	1775
an	an	DT	B-NP	O		1776	1778
LPS	LPS	NN	I-NP	O		1779	1782
-	-	HYPH	B-NP	O		1782	1783
specific	specific	JJ	I-NP	O		1783	1791
MAb	MAb	NN	I-NP	B-protein		1792	1795
can	can	MD	B-VP	O		1796	1799
neutralize	neutralize	VB	I-VP	O		1800	1810
C. burnetii	C._burnetii	NNP	B-NP	O		1811	1822
infection	infection	NN	I-NP	O		1823	1832
and	and	CC	O	O		1833	1836
appears	appear	VBZ	B-VP	O		1837	1844
to	to	TO	I-VP	O		1845	1847
be	be	VB	I-VP	O		1848	1850
a	a	DT	B-NP	O		1851	1852
promising	promising	JJ	I-NP	O		1853	1862
step	step	NN	I-NP	O		1863	1867
toward	toward	IN	B-PP	O		1868	1874
the	the	DT	B-NP	O		1875	1878
potential	potential	JJ	I-NP	O		1879	1888
use	use	NN	I-NP	O		1889	1892
of	of	IN	B-PP	O		1893	1895
a	a	DT	B-NP	O		1896	1897
humanized	humanized	JJ	I-NP	B-protein		1898	1907
MAb	MAb	NN	I-NP	I-protein		1908	1911
as	as	IN	B-PP	O		1912	1914
emergency	emergency	NN	B-NP	O		1915	1924
prophylaxis	prophylaxis	NN	I-NP	O		1925	1936
against	against	IN	B-PP	O		1937	1944
C. burnetii	C._burnetii	NNP	B-NP	O		1945	1956
exposure	exposure	NN	I-NP	O		1957	1965
.	.	.	O	O		1965	1966

